Cattran Ashley, Elwing Jean
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio, USA
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
BMJ Case Rep. 2021 Mar 25;14(3):e235806. doi: 10.1136/bcr-2020-235806.
Chronic thromboembolic pulmonary hypertension (CTEPH) involves non-resolving thromboemboli in the pulmonary arteries. Treatment for CTEPH includes lifelong anticoagulation and determination of patients who have disease which is operable versus inoperable. Pulmonary arterial hypertension (PAH) targeted therapies are oftentimes used as a bridge to pulmonary thromboendarterectomy (PTE), though riociguat is the only Food and Drug Administration (FDA)-approved therapy for CTEPH. There is a paucity of data regarding the efficacy of other PAH therapies, particularly as a bridge to PTE. Here, we present a case report of severe CTEPH related to ventriculoatrial shunt in which intravenous treprostinil was used as a bridge to PTE.
慢性血栓栓塞性肺动脉高压（CTEPH）涉及肺动脉内无法溶解的血栓栓子。CTEPH的治疗包括终身抗凝以及确定疾病可手术与不可手术的患者。肺动脉高压（PAH）靶向治疗常常被用作肺血栓内膜剥脱术（PTE）的过渡治疗，尽管利奥西呱是美国食品药品监督管理局（FDA）批准的唯一用于CTEPH的治疗药物。关于其他PAH治疗疗效的数据很少，尤其是作为PTE的过渡治疗。在此，我们报告一例与心室心房分流相关的严重CTEPH病例，其中静脉注射曲前列尼尔被用作PTE的过渡治疗。
